arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Hyperfine, Inc.

HYPR
$0.69 ▼ -0.06 (-8.04%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
24 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

Hyperfine, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $68.9M
Dividend Yield —
Revenue Growth 44.8% ↘
Op. Margin -216.9% →
ROIC -16.9% ↗
FCF / Share $-0.07 ↗
Trailing P/E —
Price / Book 1.9x
FCF Yield —
Debt / Equity 0.36
info Valuation on last close. End-of-day price, Nov 5, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.90M
↑ +44.8% —
Net Income Profit after all expenses
$-8.62M
↑ +8.4% —
Operating Margin Operating profit as % of sales
-216.9%
↑ +1.1% 0th
FCF / Share Free cash flow per share
$-0.07
↑ +32.3% —
Long-Term Debt Long-term obligations
$13.23M
↑ +0.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns ↓
11
Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 24 quarters